Aldeyra Therapeutics(ALDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALDX Aldeyra Therapeutics

Trading 11-02 15:57:17 EST

0.5751

+0.0148

+2.64%

High0.5872	Low0.5271	Vol834.03K
Open0.5601	D1 Closing0.5603	Amplitude10.73%
Mkt Cap34.60M	Tradable Cap28.14M	Total Shares60.16M
T/O457.16K	T/O Rate1.70%	Tradable Shares48.93M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ALDX","market":"US","secType":"STK","nameCN":"Aldeyra Therapeutics","latestPrice":0.5751,"timestamp":1793653030173,"preClose":0.5603,"halted":0,"volume":834034,"delay":0,"changeRate":0.026414420845975235,"floatShares":48929399,"shares":60162773,"eps":-0.383602,"marketStatus":"Trading","change":0.0148,"latestTime":"11-02 15:57:17 EST","open":0.5601,"high":0.5872,"low":0.5271,"amount":457158.68944504,"amplitude":0.107264,"askPrice":0.5908,"askSize":20,"bidPrice":0.5822,"bidSize":489,"shortable":0,"etf":0,"ttmEps":-0.383602,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1793653200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1399003200000,"exchange":"NASDAQ","adjPreClose":0.5603,"preHourTrading":{"tag":"盘前","latestPrice":0.5623,"preClose":0.5603,"latestTime":"09:28 EST","volume":40693,"amount":22874.0561704,"timestamp":1793629714275,"change":0.002,"changeRate":0.00357,"amplitude":0.0141},"postHourTrading":{"tag":"盘后","latestPrice":0.5623,"preClose":0.5603,"latestTime":"19:39 EDT","volume":2455,"amount":1376.3677,"timestamp":1793403599086,"change":0.002,"changeRate":0.00357,"amplitude":0.010709},"volumeRatio":1.097154,"impliedVol":0.1776,"impliedVolPercentile":0.0199},"requestUrl":"/m/hq/s/ALDX/","defaultTab":"news","newsList":[{"id":"2671205590","title":"Aldeyra Therapeutics: Neutral Rating Maintained Amid FDA Uncertainty; $2 Price Target Reaffirmed","url":"https://stock-news.laohu8.com/highlight/detail?id=2671205590","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671205590?lang=en_us&edition=fundamental","pubTime":"2026-09-30 18:25","pubTimestamp":1790763928,"startTime":"0","endTime":"0","summary":"Analyst Matthew Caufield of H.C. Wainwright reiterated a Hold rating on Aldeyra Therapeutics, retaining the price target of $2.00. Matthew Caufield...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/aldeyra-therapeutics-neutral-rating-maintained-amid-fda-uncertainty-2-price-target-reaffirmed-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/aldeyra-therapeutics-neutral-rating-maintained-amid-fda-uncertainty-2-price-target-reaffirmed-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALDX","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671491246","title":"Aldeyra Therapeutics Price Target Maintained with a $9.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2671491246","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671491246?lang=en_us&edition=fundamental","pubTime":"2026-09-30 00:40","pubTimestamp":1790700000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALDX/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671268216","title":"Aldeyra to submit Formal Dispute Resolution Request to FDA for reproxalap","url":"https://stock-news.laohu8.com/highlight/detail?id=2671268216","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671268216?lang=en_us&edition=fundamental","pubTime":"2026-09-29 19:10","pubTimestamp":1790680247,"startTime":"0","endTime":"0","summary":"Aldeyra (ALDX) Therapeutics announced intent to submit to the U.S. Food and Drug Administration a Formal Dispute Resolution Request for reproxalap,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aldeyra-to-submit-formal-dispute-resolution-request-to-fda-for-reproxalap-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aldeyra-to-submit-formal-dispute-resolution-request-to-fda-for-reproxalap-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALDX","LABU","BK4588","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671821629","title":"Aldeyra sees operational cash runway into 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2671821629","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671821629?lang=en_us&edition=fundamental","pubTime":"2026-09-29 19:10","pubTimestamp":1790680237,"startTime":"0","endTime":"0","summary":"Based on reported cash and cash equivalents of $45.1M as of June 30, 2026, Aldeyra (ALDX) updated financial guidance to include extension of operat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aldeyra-sees-operational-cash-runway-into-2029-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aldeyra-sees-operational-cash-runway-into-2029-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671168322","title":"Aldeyra Extends Operational Cash Runway into 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2671168322","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671168322?lang=en_us&edition=fundamental","pubTime":"2026-09-29 19:02","pubTimestamp":1790679738,"startTime":"0","endTime":"0","summary":"Aldeyra extends operational cash runway into 2029Aldeyra updated financial guidance to extend its operational cash runway into 2029.Update reflects reported cash and cash equivalents of $45.1 million ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nNDL5SljDr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671721502","title":"Aldeyra Therapeutics - Fdrr Submission and FDA Meeting Expected in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2671721502","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671721502?lang=en_us&edition=fundamental","pubTime":"2026-09-29 19:00","pubTimestamp":1790679602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nTUA3XQBPR:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671157382","title":"Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2671157382","media":"THOMSON REUTERS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671157382?lang=en_us&edition=fundamental","pubTime":"2026-09-29 19:00","pubTimestamp":1790679602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nTUA3XQBPR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671022215","title":"Aldeyra Therapeutics - Fdrr to Appeal March 16, 2026 Complete Response Letter Denying Nda for Reproxalap","url":"https://stock-news.laohu8.com/highlight/detail?id=2671022215","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671022215?lang=en_us&edition=fundamental","pubTime":"2026-09-29 19:00","pubTimestamp":1790679602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nTUA3XQBPR:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ALDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669167067","title":"Aldeyra Therapeutics (ALDX) Receives a Hold from H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2669167067","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669167067?lang=en_us&edition=fundamental","pubTime":"2026-09-22 01:55","pubTimestamp":1790013337,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Matthew Caufield maintained a Hold rating on Aldeyra Therapeutics today and set a price target of $2.00. According to TipRa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/aldeyra-therapeutics-aldx-receives-a-hold-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/aldeyra-therapeutics-aldx-receives-a-hold-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ALDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657666518","title":"Aldeyra Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657666518","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657666518?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:37","pubTimestamp":1786052269,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryAldeyra Therapeutics IncALDX.OQreported a quarterly adjusted loss of 9 cents per share for the quarter ended Ju","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4433GN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657509656","title":"Aldeyra Net Loss Narrows 44.2% to $5.45 Million in Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2657509656","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657509656?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:17","pubTimestamp":1786047463,"startTime":"0","endTime":"0","summary":"Aldeyra net loss narrows 44.2% to $5.45 million in Q2 2026Aldeyra Therapeutics posted a GAAP net loss of USD 5.45 million for Q2 2026, narrowing 44.2% from a loss of USD 9.77 million.Operating loss im","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL8BZSPN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALDX","IYH","LU0211328371.USD","IE000F7OJYX1.SGD","XLV","LU2129689605.HKD","LU0256863902.USD","LU0158827948.USD","LU1023059063.AUD","SG9999015952.SGD","AGNG","LU0689472784.USD","PJP","LU0395794307.EUR","RXL","IXJ","BK4534","FTXH","ABBV","LU1244550494.USD","LU2125909593.SGD","LU0553294199.USD","LU1839511570.USD","LU0058720904.USD","LU0820561909.HKD","LU0289961442.SGD","VHT","LU0545039389.USD","LU0203347892.USD","LU1989772923.USD","TRUH","SG9999015978.USD","LU0965508806.USD","LU0708994859.HKD","LU1934455194.USD","JDOC","FHLC","IE00B19Z3581.USD","LU1037948541.HKD","LU1496350171.SGD","IE000WAW04H5.SGD","MEDX","LU1037948897.HKD","LU0234572021.USD","PPH","IE00B42XCP33.USD","IE000BZT7R73.USD","GLAM","BK4533","LU2089284900.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656300614","title":"Aldeyra Therapeutics Inc Expected to Post a Loss of 9 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2656300614","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656300614?lang=en_us&edition=fundamental","pubTime":"2026-08-04 06:31","pubTimestamp":1785796318,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics Inc <ALDX.OQ> expected to post a loss of9cents a share - Earnings PreviewAldeyra Therapeutics IncALDX.OQALDX.Ois expected to  show no change in quarterly revenue when it reports  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL8N4402OH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ALDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655524433","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2655524433","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655524433?lang=en_us&edition=fundamental","pubTime":"2026-07-31 18:00","pubTimestamp":1785492000,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.Company                                   Symbol     Quarter  Mean  Report Time. ·Arbor Rlty Tr.                                    2Q       .05    8:30 AM. ·Church & Dwight                                   2Q       .90    6:55 AM. ·Eaton Corp. Plc                                   2Q      3.07    6:30 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALDX","CLPT","BHVN","BRK.B","CLX","CSR","CRD.B","BWXT","BCBP","ADUS","AESI","BCC","CBT","CTOS","AEIS","ALG","ABBV","CRD.A","CSWC","CVX","BLZE","BLDP","CNH","AN","ANDE","BRK.A","BEP","BSM","BEN","CVGI","CLAR","CHD","ARES","CRGY","ADEA","BTSG","CGEN","AU","CL","ALSN","CRI","D","BMEA","CCJ","MOG.B","ABR","ARE","AMRC","AVA","ADTN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655231381","title":"Aldeyra Therapeutics Leases New Concord Headquarters Space","url":"https://stock-news.laohu8.com/highlight/detail?id=2655231381","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655231381?lang=en_us&edition=fundamental","pubTime":"2026-07-31 05:36","pubTimestamp":1785447366,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics ( ($ALDX) ) just unveiled an update. On July 28, 2026, Aldeyra Therapeutics executed a lease agreement with Bradford Street, L...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aldeyra-therapeutics-leases-new-concord-headquarters-space?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aldeyra-therapeutics-leases-new-concord-headquarters-space?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ALDX","CNDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651445490","title":"Aldeyra Therapeutics Seeks FDA Clarification on Reproxalap NDA Meeting Minutes","url":"https://stock-news.laohu8.com/highlight/detail?id=2651445490","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651445490?lang=en_us&edition=fundamental","pubTime":"2026-07-16 18:44","pubTimestamp":1784198647,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics (ALDX) said Thursday it received meeting minutes from the US Food and Drug Administration regarding the potential resubmission of its new drug application for reproxalap to treat ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4585","ALDX","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651496271","title":"Aldeyra Therapeutics - to Request FDA Type D Meeting on Nda of Reproxalap Resubmission by End of Q3 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2651496271","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651496271?lang=en_us&edition=fundamental","pubTime":"2026-07-16 04:59","pubTimestamp":1784149153,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nFWN43H1CR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ALDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649607056","title":"Levicept Appoints Darlene Deptula-hicks as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2649607056","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649607056?lang=en_us&edition=fundamental","pubTime":"2026-07-07 16:00","pubTimestamp":1783411200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nTUA2TFNVJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ALDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642923140","title":"Aldeyra Therapeutics director Darlene Deptula-Hicks files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2642923140","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642923140?lang=en_us&edition=fundamental","pubTime":"2026-06-12 04:13","pubTimestamp":1781208828,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics director Darlene Deptula-Hicks filed an initial Form 3 on June 11, dated June 9.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 11, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDLbbh3W3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642415216","title":"Aldeyra Therapeutics appoints Darlene Deptula-Hicks to board of directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2642415216","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642415216?lang=en_us&edition=fundamental","pubTime":"2026-06-10 08:30","pubTimestamp":1781051414,"startTime":"0","endTime":"0","summary":"Aldeyra Therapeutics named Darlene Deptula-Hicks to its board as it moves toward potential commercialization of its immune-mediated disease pipeline.Deptula-Hicks is acting CFO at Normunity, a clinical-stage cancer biotech.She previously served as CFO of F-star Therapeutics.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aldeyra Therapeutics Inc. published the original content used to generate this news brief via Business Wire  on June 10, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nNDL7Lqcdx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","ALDX","01177","BK1589","BK1521","IE00BZ08YS42.EUR","BK4139","BK1515","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642250415","title":"Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2642250415","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642250415?lang=en_us&edition=fundamental","pubTime":"2026-06-10 08:30","pubTimestamp":1781051400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nTUA3MF4XT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aldeyra.com;ir.aldeyra.com","stockEarnings":[{"period":"1week","weight":-0.1376},{"period":"1month","weight":-0.5445},{"period":"3month","weight":-0.6362},{"period":"6month","weight":-0.6476},{"period":"1year","weight":-0.8886},{"period":"ytd","weight":-0.8918}],"compareEarnings":[{"period":"1week","weight":-0.0056},{"period":"1month","weight":-0.0091},{"period":"3month","weight":0.0116},{"period":"6month","weight":0.0487},{"period":"1year","weight":0.1116},{"period":"ytd","weight":0.1082}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.583333,"avgChangeRate":0.071524},{"month":2,"riseRate":0.583333,"avgChangeRate":-0.000501},{"month":3,"riseRate":0.416667,"avgChangeRate":-0.048652},{"month":4,"riseRate":0.416667,"avgChangeRate":-0.015598},{"month":5,"riseRate":0.416667,"avgChangeRate":0.023947},{"month":6,"riseRate":0.384615,"avgChangeRate":0.046727},{"month":7,"riseRate":0.538462,"avgChangeRate":0.027216},{"month":8,"riseRate":0.461538,"avgChangeRate":0.043569},{"month":9,"riseRate":0.461538,"avgChangeRate":0.143731},{"month":10,"riseRate":0.384615,"avgChangeRate":-0.126752},{"month":11,"riseRate":0.666667,"avgChangeRate":0.079554},{"month":12,"riseRate":0.416667,"avgChangeRate":-0.031913}],"exchange":"NASDAQ","name":"Aldeyra Therapeutics","nameEN":"Aldeyra Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aldeyra Therapeutics(ALDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aldeyra Therapeutics(ALDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aldeyra Therapeutics,ALDX,Aldeyra Therapeutics股票,Aldeyra Therapeutics股票老虎,Aldeyra Therapeutics股票老虎国际,Aldeyra Therapeutics行情,Aldeyra Therapeutics股票行情,Aldeyra Therapeutics股价,Aldeyra Therapeutics股市,Aldeyra Therapeutics股票价格,Aldeyra Therapeutics股票交易,Aldeyra Therapeutics股票购买,Aldeyra Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aldeyra Therapeutics(ALDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aldeyra Therapeutics(ALDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}